- Home
- OCCI vs RAPT Comparison
OCCI vs RAPT Comparison
Compare OCCI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCCI
- RAPT
- Stock Information
- Founded
- OCCI N/A
- RAPT 2015
- Country
- OCCI United States
- RAPT United States
- Employees
- OCCI N/A
- RAPT N/A
- Industry
- OCCI Trusts Except Educational Religious and Charitable
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- OCCI Finance
- RAPT Health Care
- Exchange
- OCCI Nasdaq
- RAPT Nasdaq
- Market Cap
- OCCI 146.8M
- RAPT 117.5M
- IPO Year
- OCCI N/A
- RAPT 2019
- Fundamental
- Price
- OCCI $6.44
- RAPT $0.79
- Analyst Decision
- OCCI
- RAPT Hold
- Analyst Count
- OCCI 0
- RAPT 7
- Target Price
- OCCI N/A
- RAPT $5.00
- AVG Volume (30 Days)
- OCCI 115.8K
- RAPT 1.1M
- Earning Date
- OCCI 12-11-2023
- RAPT 05-08-2025
- Dividend Yield
- OCCI 24.32%
- RAPT N/A
- EPS Growth
- OCCI N/A
- RAPT N/A
- EPS
- OCCI N/A
- RAPT N/A
- Revenue
- OCCI N/A
- RAPT N/A
- Revenue This Year
- OCCI N/A
- RAPT N/A
- Revenue Next Year
- OCCI $10.19
- RAPT N/A
- P/E Ratio
- OCCI N/A
- RAPT N/A
- Revenue Growth
- OCCI N/A
- RAPT N/A
- 52 Week Low
- OCCI $5.47
- RAPT $0.79
- 52 Week High
- OCCI $10.15
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- OCCI 48.76
- RAPT 31.31
- Support Level
- OCCI $6.23
- RAPT $0.81
- Resistance Level
- OCCI $6.70
- RAPT $0.98
- Average True Range (ATR)
- OCCI 0.32
- RAPT 0.10
- MACD
- OCCI 0.07
- RAPT -0.03
- Stochastic Oscillator
- OCCI 81.94
- RAPT 7.72
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.